jilibet 018

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com ALLO-316, an allogeneic CD70-directed CAR T-cell therapy, demonstrated preliminary activity and a manageable safety profile in patients with advanced or metastatic CD70-positive clear cell renal cell carcinoma (ccRCC), according to findings from the phase 1a portion of the phase 1a/1b TRAVERSE trial (NCT04696731) presented at the 2024 SITC Annual Meeting . Among the 39 patients enrolled, 26 were CD70 positive and evaluable for efficacy outcomes, with the highest responses observed in patients with a tumor proportion score (TPS) of at least 50 (n = 21). Tumor reduction was notably greater in CD70-positive patients with a TPS of at least 50, with 76% of patients (n = 16) achieving tumor burden reductions and 33% of patients (n = 7) experiencing a reduction of greater than 30%. Dose-limiting toxicities (DLTs) were observed in 2 patients, both of whom received FCA (fludarabine, cyclophosphamide, and alemtuzumab [Lemtrada]) lymphodepletion followed by ALLO-316 at dose level 2 (DL2). These DLTs were autoimmune hepatitis (n = 1) and cardiogenic shock in the setting of multiorgan failure (n = 1). Treatment-emergent adverse effects (TEAEs) were observed in all 39 patients, with 81% of patients experiencing grade 3 or higher TEAEs. The most common TEAEs included cytokine release syndrome (CRS; any-grade, 62%; grade ≥ 3, 3%), fatigue (59%; 3%), and neutropenia (56%; 51%). No graft-vs-host disease was reported In the poster, lead study author Samer Srour, MS, MD, and coauthors, explained, “observed responses, including ongoing and deepening responses, in patients with a CD70 TPS [of at least] 50%, [indicate] a single infusion of ALLO-316 could benefit patients with immune checkpoint inhibitor– and TKI-relapsed/refractory RCC.” Srour is an assistant professor in the Department of Stem Cell Transplantation and Cellular Therapy in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Phase 1a of the trial employed a standard dose-escalation design to primarily evaluate DLTs and the incidence of AEs. Phase 1b primarily focused on identifying the recommended phase 2 dose of ALLO-316, establishing the optimal CD70 TPS cutoff, and assessing the incidence of AEs. Secondary end points across both phases included assessments of objective response rate (ORR), complete response rate, duration of response, time to response, progression-free survival, CAR expansion kinetics, and CD70 expression on tumor cells. Patients older than 18 years of age were eligible for enrollment in the TRAVERSE study and were required to have progressive advanced or metastatic ccRCC following prior immune checkpoint inhibitor and VEGF-targeted therapy. Additional enrollment criteria included an ECOG performance status of 0 or 1, adequate organ function, and no untreated central nervous system metastases. CD70 expression was assessed via immunohistochemistry on archival or fresh tumor tissue to confirm eligibility. Patients received lymphodepletion from days –5 to –3, followed by a single infusion of ALLO-316 on day 0. The trial included comprehensive follow-up to assess safety and efficacy through 60 months. The median patient age was 60 years (range, 35-70), and most patients were male (90%). Regarding performance status, 56% of patients had an ECOG PS of 0 or 1. Nearly all patients had stage IV disease (97%), and 82% of patients had undergone prior nephrectomy. The median time since original diagnosis was 43 months (range, 12-216), and the median number of prior therapy lines was 3 (range, 1-8). All patients had received prior anti–PD-1 therapy, and 1 patient had received anti–PD-L1 therapy. Sixty-four percent of patients had received prior anti–CTLA-4 therapy. All patients had received at least 1 prior TKI, 59% of patients had received at least 2 prior TKIs, and 28% of patients had received at least 3 prior TKIs. Additionally, 79% of patients had been previously treated with cabozantinib (Cabometyx), and 8% of patients had progressive disease despite anti–CTLA-4, anti–PD-1, TKI, and belzutifan (Welireg) therapy. CD70 positivity was observed in 79% of patients, with 77% of patients having high TPS (≥ 50%) and 23% of patients having low TPS (< 50%). CD70-negative or -unknown status was reported in 21% of patients. Based on the International Metastatic RCC Database Consortium risk categories, 33% of patients were classified as favorable risk, 51% of patients were classified as intermediate risk, and 10% of patients were classified as poor risk. The median time from enrollment to lymphodepletion was 5 days (range, 1-10), and the median duration of follow-up was 6.8 months (range, 0.4-36.8). Among the 39 enrolled patients, 35 received ALLO-316, and 34 were evaluable for disease outcomes. Stratification was based on CD70 expression, with 26 patients identified as CD70 positive. These patients received treatment across 4 dose levels of ALLO-316. At dose level 1 (40 x 106 cells), 3 patients were treated following FCA lymphodepletion. DL2 (80 x 106 cells) included 16 patients, with 5 receiving FCA and 3 receiving FC300 lymphodepletion. Eight patients are planned to receive FC500 lymphodepletion at DL2 in the phase 1b portion of the trial. Dose level 3 (120 x 106 cells) included 6 patients who were evenly split between the FC300 and FC500 lymphodepletion regimens, whereas dose level 4 (240 x 106 cells) included 1 patient treated with FC300 lymphodepletion. Five patients were CD70 negative, and 3 patients had unknown CD70 expression. These patients received treatment across various dose levels but were not included in the primary efficacy analysis. In the CD70-positive cohort, the best ORR was 27% (n = 7), and responses were exclusively observed in patients with a TPS of at least 50. Confirmed responses were achieved in 24% (n = 5) of these patients. In the FCA cohort (n = 8), a single confirmed response was observed in 1 patient with a high TPS (13%). In the FC cohort (n = 18), the ORR was 33% (n = 6), with confirmed responses reported in 22% of patients (n = 4). Patients treated at DL2 with FC500 had an ORR of 38% (n = 3), with confirmed responses in 25% of patients (n = 2). In this cohort, 2 patients (25%) had durable responses lasting beyond 4 months. Other common TEAEs included decreased white blood cell (WBC) counts (any-grade, 54%; grade ≥ 3, 49%), anemia (51%; 33%), nausea (51%; 0%), thrombocytopenia (46%; 26%), pyrexia (41%; 5%). AEs of special interest included infections (any-grade, 62%; grade ≥ 3, 31), including viral infections (33%; 5%); neurotoxicity (44%; 8%), including headache (21%; 0%); and immune effector cell–associated hemophagocytosis-like syndrome (IEC-HS; 13%; 3%). Immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 8% of patients, although no grade 3 or higher ICANS was reported. Investigators outlined recommended IEC-HA management guidance, which included ruxolitinib (Jakafi) and the consideration of dexamethasone with or without anakinra (Kineret) in the frontline setting. If responses were insufficient within 24 to 48 hours, recommended second-line therapy consisted of the addition of dexamethasone with or without anakinra (if not already added in the frontline setting); if no improvement was observed after 24 hours, dosing of ruxolitinib/dexamethasone/anakinra could be escalated. If second-line responses were insufficient within 24 to 48 hours, third-line treatment could consist of emapalumab (Gamifant) or etoposide and/or an “off switch” for adoptive cellular therapy. Fatal treatment-related AEs included cardiogenic shock (a DLT), sepsis, and failure to thrive in 1 patient 16 months after their last treatment. TEAEs observed among patients treated at DL2 who received FC500 lymphodepletion (n = 11), were consistent with those seen in the overall population. In this population, the most frequently observed TEAEs were CRS (any-grade, 73%; grade ≥ 3, 0%), fatigue (18%; 0%), neutropenia (64%; 64%), decreased WBC counts (73%; 73%), anemia (64%; 46%), and thrombocytopenia (64%; 27%). Vector copy number (VCN) levels were evaluated over time in peripheral blood and tumor biopsy samples. In responders, VCN levels peaked between approximately days 7 and 21 following CAR T-cell infusion and declined gradually beyond day 56. In contrast, nonresponders exhibited lower VCN levels with minimal expansion over the same period. Tumor biopsy samples showed high VCN levels, highlighting the targeted infiltration of ALLO-316 into the tumor microenvironment. The Dagger effect was characterized by the elimination of CD70-positive host T cells in all evaluable patients by day 10. In contrast, levels of CD70-negative host T cells were generally preserved. This effect was accompanied by robust expansion of ALLO-316 CAR T cells, as evidenced by flow cytometry. By day 56, recovery of CD70-positive host T cells was observed, coinciding with contraction of CAR T cells. “The CD70 CAR-intrinsic Dagger effect promotes robust expansion and persistence of ALLO-316 with standard FC lymphodepletion, highlighting the potential of Dagger technology as the next-generation allogeneic platform,” the authors concluded. “The phase 1 TRAVERSE study supports further evaluation of ALLO-316 in CD70-positive ccRCC and other CD70-positive malignancies. Enrollment is ongoing at the phase 1b dose regimen of FC500 and 80 x 10 6 CAR T cells.” Srour SA, Chahoud J, Drakaki A , et al. ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study. J Immunother Cancer . 2024;12(suppl 2). doi:10.1136/jitc-2024-SITC2024.0322As Americans are beyond burned out, Tricia Hersey’s Nap Ministry preaches the right to rest

Pro Football Hall of Fame reveals 2025 finalists as one nominee ignites controversy 44 years after tragedyVirtual Fitting Room Market New Opportunities to 2031 True Fit Corporation, Else Corp Srl, Metail Limited, Fit Analytics GmbH, Zugara, 12-05-2024 08:56 PM CET | Fashion, Lifestyle, Trends Press release from: STATS N DATA Virtual Fitting Room Market [New York, December 2024] The Virtual Fitting Room market is redefining the shopping experience by enabling customers to try on clothes virtually, enhancing online retail and reducing return rates. This innovative technology combines augmented reality (AR) and artificial intelligence (AI) to create immersive fitting experiences for users, ensuring they find the right size and style without requiring physical interaction. As e-commerce continues to surge, the relevance of virtual fitting rooms becomes paramount. This technology not only offers convenience to consumers but also significantly benefits retailers by optimizing inventory management and minimizing the environmental impact associated with returns. The growing demand for personalized shopping experiences has made virtual fitting rooms a critical component in the retail landscape. You can access a sample PDF report here: https://www.statsndata.org/download-sample.php?id=8174 As the Virtual Fitting Room market continues to evolve, significant growth opportunities lie ahead. Retailers and industry players who adopt this technology stand to enhance customer engagement while driving sales. The next few years will see an influx of investment and innovation in virtual fitting room solutions. Existing players can deepen their market presence by leveraging advanced AI algorithms that cater to diverse consumer preferences. Simultaneously, new entrants will find fertile ground for establishing a foothold in this dynamic market by offering unique virtual fitting experiences. The ongoing shift towards digital transformation and consumer reliance on online shopping make this an opportune time for investments in virtual fitting room technology. In reflecting on its evolution, the Virtual Fitting Room market has transitioned from early-stage experimentation to a robust existence that caters to both large brands and niche retailers. Trends indicate that consumer behavior is gravitating towards more immersive and engaging shopping experiences, driving demand for enhanced virtual fitting solutions. Today, industry leaders who embraced this technology have reaped the rewards of increased sales and customer loyalty. Nonetheless, market restraints such as initial investment costs and technological integration challenges exist. However, despite these barriers, the significant growth potential of the Virtual Fitting Room market presents exciting opportunities for strategic investment. Aspiring players are encouraged to explore this innovative landscape, as the future heralds greater technological advancements and broader market adoption.In today's rapidly evolving market, informed decision-making is crucial for staying competitive. STATS N DATA's Global Virtual Fitting Room Market Report offers a comprehensive analysis of current trends and future growth opportunities from 2024 to 2031. With expert forecasts and data-driven insights, this report empowers businesses and investors to make strategic choices that enhance their competitive edge. This report serves as a key resource, detailing current Virtual Fitting Room market conditions and identifying factors expected to drive growth in the coming years. With industry expertise, it enables companies to plan around emerging trends and build a sustainable competitive advantage. The Global Virtual Fitting Room Market has shown steady growth, propelled by technological innovations and rising demand across sectors. STATS N DATA's report explores this growth and the factors fueling it. Main Growth Drivers and Challenges The Virtual Fitting Room report highlights core drivers like new technology and changing consumer demands, as well as challenges such as regulatory shifts and economic uncertainties. This dual perspective supports businesses in creating strategies that maximize growth potential while managing risks, promoting long-term resilience. Comprehensive Segmentation Analysis To provide specific insights, the Global Virtual Fitting Room Market is divided into key segments: Market Segmentation: By Type • Apparel • Beauty and Cosmetics • Eyewear • Footwear • Jewelry and Watches Market Segmentation: By Application • Software • Hardware • Service Each segment is thoroughly analyzed, presenting insights into Virtual Fitting Room market size, growth potential, and trends. This helps companies target high-growth areas and allocate resources strategically. The report also includes an attractiveness analysis, assessing each segment's potential based on competition and market opportunity in the it-telecom industry. Regional Insights for Global Reach The report includes a comprehensive regional analysis of the Global Virtual Fitting Room Market, covering North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. This breakdown is ideal for businesses seeking expansion or customizing their strategies to specific regions, with high-growth areas highlighted for new opportunities and local Virtual Fitting Room market needs. Get 30% Discount On Full Report: https://www.statsndata.org/ask-for-discount.php?id=8174 Competitive Landscape and Technology Trends As the Virtual Fitting Room Market evolves, so does the competitive landscape. This report profiles the top players, with insights into their strategies, including mergers, acquisitions, and product innovations. Key players include: • 3D-A-Porter Ltd. • Autumn Rock Limited (AstraFit) • True Fit Corporation • Else Corp Srl • Metail Limited • Fit Analytics GmbH • Zugara, • Coitor IT Tech Private Limited • Sizebay • Magic Mirror • Youbuy3D S.L. (Visualook) • Fision AG • FXGear, • MemoMi Labs, • SenseMi Smart Solutions • Quakeup Media Production, (triMirror) • Virtusize • Reactive Reality AG Additionally, the report examines the latest technological advancements influencing the market, guiding companies on leveraging innovation to stay ahead. Regulatory and Economic Analysis Regulations impact the Virtual Fitting Room Market's growth, and this report provides a detailed review of key regulatory guidelines. It also covers economic factors like GDP growth, inflation, and employment trends, enabling companies to develop strategies that adapt to regulatory and economic changes. In summary, STATS N DATA's Global Virtual Fitting Room Market Report provides essential insights on trends, competition, and growth opportunities, helping businesses and investors make better-informed decisions for success in a competitive and evolving market. For customization requests, please visit: : https://www.statsndata.org/request-customization.php?id=8174 https://www.statsndata.org/report/virtual-fitting-room-market-8174 John Jones Sales & Marketing Head | Stats N Data Phone: +1 (315) 642-4324 Email: sales@statsndata.org Website: www.statsndata.org STATS N DATA is a trusted provider of industry intelligence and market research, delivering actionable insights to businesses across diverse sectors. We specialize in helping organizations navigate complex markets with advanced analytics, detailed market segmentation, and strategic guidance. Our expertise spans industries including technology, healthcare, telecommunications, energy, food & beverages, and more. Committed to accuracy and innovation, we provide tailored reports that empower clients to make informed decisions, identify emerging opportunities, and achieve sustainable growth. Our team of skilled analysts leverages cutting-edge methodologies to ensure every report addresses the unique challenges of our clients. At STATS N DATA, we transform data into knowledge and insights into success. Partner with us to gain a competitive edge in today's fast-paced business environment. For more information, visit https://www.statsndata.org or contact us today at sales@statsndata.org This release was published on openPR.

NORMAN, Okla. (AP) — Oklahoma appears to have borrowed from the past to cure its recent offensive ills. The Sooners , best known this century for a passing prowess that has produced four Heisman Trophy-winning quarterbacks, took it back to the 20th century against then-No. 7 Alabama. Oklahoma ran 50 times for 257 yards while only throwing 12 times in a 24-3 win over the Crimson Tide that took coach Brent Venables off the hot seat. The Sooners more resembled Barry Switzer’s squads that dominated the old Big 8 with the wishbone offense in the 1970s and ’80s than the more recent Air Raid teams. Venables said the change was a matter of necessity for a unit that has been besieged by injuries at receiver and offensive line. “I think this staff has done a really good job with trying to figure that out, get better every week, put together a great gameplan but also figure out, ‘OK, what does this group of guys, what does this team — what do we need to do?'” Venables said. To make it work, Oklahoma needed to trust that such a change would work in the modern Southeastern Conference. They had to implement it with an interim play-caller in Joe Jon Finley, who stepped in after the Sooners fired Seth Littrell last month. Oklahoma (6-5, 2-5 SEC) pulled it off, and LSU coach Brian Kelly has taken notice ahead of their game on Saturday. “This is now much more about controlling the football, running the football, playing with physicality," Kelly said. "They've got perimeter skill, but I think it's centered around much more of a run-centric, quarterback run and take care of the football." The Sooners started to see success on the ground against Maine. They ran 52 times for 381 yards in a 59-14 win that got the wheels turning. Jovantae Barnes ran for career highs of 203 yards and three touchdowns that day. Venables said the timing of the opportunity to play that non-conference game against Maine in early November and figure some things out was perfect. “Everybody has some degree of vulnerability and maybe some self-doubt,” he said. “And just developing some confidence and putting something on tape other than practice, like, ‘Man, look, see what you’re capable of?’ And executing against, again, a well-coached team — certainly, we played off of that in all the right ways like you would expect us to. And so there’s a real place for that.” Story continues below video After a bye week, the Sooners tried the same approach against Missouri. It wasn't as successful — they ran 36 times for 122 yards — but they hung tough before losing 30-23 . The Sooners went all in against Alabama. Jackson Arnold — the same guy who threw 45 times in the Alamo Bowl last year, ran 25 times for 131 yards and threw just 11 passes. The Sooners found something in running back Xavier Robinson. With Barnes out with an injury, Robinson carried 18 times for career highs of 107 yards and two touchdowns. Suddenly, a team that had been forcing the pass and getting sacked at an alarming rate was moving the line of scrimmage and controlling the tempo. Oklahoma had the ball for more than 34 minutes against the Crimson Tide, lending support to a talented defense that had been spending way too much time on the field. The new approach could be helpful on Saturday — LSU (7-4, 4-3) ranks 14th out of 16 conference teams against the run. Venables said the Sooners still need to throw the ball well to win, but he's glad to know his squad can run with force when necessary. “I think that’s the art of having a system that’s adjustable, flexible, adaptable, week in and week out, but also has an identity — toughness, physicality," he said. "You’ve got to be able to run the ball at every level of football, but you do have to throw it. You can’t just do one thing. But we need to be efficient.” Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

President-elect Donald Trump’s lawyers urge judge to toss his hush money convictionSAN JOSE, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutanix , Inc. NTNX , a leader in hybrid multicloud computing, today announced that its management will present at the following upcoming financial community event: Barclays 22 nd Annual Global Technology Conference Thursday, December 12, 2024 10:25 a.m. PST; 1:25 p.m. EST A live webcast and replay of the presentation will be accessible on the Nutanix Investor Relations website at ir.nutanix.com About Nutanix Nutanix is a global leader in cloud software, offering organizations a single platform for running applications and managing data, anywhere. With Nutanix, companies can reduce complexity and simplify operations, freeing them to focus on their business outcomes. Building on its legacy as the pioneer of hyperconverged infrastructure, Nutanix is trusted by companies worldwide to power hybrid multicloud environments consistently, simply, and cost-effectively. Learn more at www.nutanix.com or follow us on social media @nutanix. © 2024 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo, and all Nutanix product and service names mentioned herein are registered trademarks or unregistered trademarks of Nutanix, Inc. in the United States and other countries. Other brand names and marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s). I nvestor Contact Richard Valera ir@nutanix.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

President-elect Donald Trump’s lawyers urge judge to toss his hush money conviction